Janssen promises full focus on Darzalex after defeating Genmab in court
Although a ruling in Janssens favor comes as a slap in the face to its partner Genmab, the former has promised to continue to support bestseller drug Darzalex.
by benjamin werner christensen, translated by catherine brett
While Genmab remains tight-lipped about its defeat in court over a royalties dispute with partner Janssen, the latter has been a little more outspoken about the expected consequences of the ruling.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab loses royalties case against Janssen
For subscribers
CEO van de Winkel wants long tenure at Genmab
For subscribers
.jpg&w=384&q=75)
